Adalimumab Biosimilar Market
完整報告名稱與涵蓋範圍
Adalimumab Biosimilar Market Size, Share & Trends Analysis Report By Product (Amjevita, Cyltezo, Hadlima, Yusimry, Hulio, Hymiroz, Abrilada, Yuflyma, Exemptia, Adalirel, Cipleumab and other pipeline products), By Application, By Distribution Channel, By Region, And By Segment Forecasts, 2025-2034
報告摘要
The global Adalimumab Biosimilar Market is forecasted to witness considerable expansion over the coming years.
At its core, Adalimumab Biosimilar pertains to a human monoclonal antibody that inhibits tumor necrosis factor (tnf), which represents a soluble inflammatory cytokine, to treat autoimmune disorders. Stakeholders across the healthcare landscape are expandingly turning to these solutions to meet contemporary demands.
Growth is supported by a convergence of factors: rising awareness among end users, continuous product innovation, and the expanding emphasis on efficiency and sustainability within the healthcare sector.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
From a regional perspective, mature markets in North America and Europe continue to hold considerable shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and expanding investment in the sector.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Adalimumab Biosimilar Market Snapshot
Chapter 4. Global Adalimumab Biosimilar Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Clinical Trial/Pipeline Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Product, Estimates & Trend Analysis
5.1. By Product, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Product:
5.2.1. Amjevita
5.2.2. Cyltezo
5.2.3. Hadlima
5.2.4. Yusimry
5.2.5. Hulio
5.2.6. Hymiroz
5.2.7. Abrilada
5.2.8. Yuflyma
5.2.9. Exemptia
5.2.10. Adalirel
5.2.11. Cipleumab
5.2.12. Other pipeline products
Chapter 5. Market Segmentation 2: By Application Estimates & Trend Analysis
5.3. By Application & Market Share, 2024 & 2034
5.4. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application:
5.4.1. Rheumatoid Arthritis
5.4.2. Juvenile Idiopathic Arthritis
5.4.3. Psoriatic Arthritis
5.4.4. Crohn's Disease
5.4.5. Ankylosing Spondylitis
5.4.6. Ulcerative Colitis
5.4.7. Psoriasis
Chapter 5. Market Segmentation 3: By Distribution Channel Estimates & Trend Analysis
5.5. By Distribution Channel & Market Share, 2024 & 2034
5.6. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Distribution Channel:
5.6.1. Hospital Pharmacy
5.6.2. Online Pharmacy
5.6.3. Retail Pharmacy
5.6.4. Other Direct Distribution Channels
Chapter 5. Adalimumab Biosimilar Market Segmentation 5: Regional Estimates & Trend Analysis
5.7. North America
5.7.1. North America Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Product, 2021-2034
5.7.2. North America Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
5.7.3. North America Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021-2034
5.7.4. North America Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
5.8. Europe
5.8.1. Europe Adalimumab Biosimilar Market revenue (US$ Million) By Product, 2021-2034
5.8.2. Europe Adalimumab Biosimilar Market revenue (US$ Million) By Application, 2021-2034
5.8.3. Europe Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021-2034
5.8.4. Europe Adalimumab Biosimilar Market revenue (US$ Million) by country, 2021-2034
5.9. Asia Pacific
5.9.1. Asia Pacific Adalimumab Biosimilar Market revenue (US$ Million) By Product, 2021-2034
5.9.2. Asia Pacific Adalimumab Biosimilar Market revenue (US$ Million) By Application, 2021-2034
5.9.3. Asia Pacific Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021-2034
5.9.4. Asia Pacific Adalimumab Biosimilar Market revenue (US$ Million) by country, 2021-2034
5.10. Latin America
5.10.1. Latin America Adalimumab Biosimilar Market revenue (US$ Million) By Product, (US$ Million) 2021-2034
5.10.2. Latin America Adalimumab Biosimilar Market revenue (US$ Million) By Application, (US$ Million) 2021-2034
5.10.3. Latin America Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021-2034
5.10.4. Latin America Adalimumab Biosimilar Market revenue (US$ Million) by country, 2021-2034
5.11. Middle East & Africa
5.11.1. Middle East & Africa Adalimumab Biosimilar Market revenue (US$ Million) By Product, (US$ Million) 2021-2034
5.11.2. Middle East & Africa Adalimumab Biosimilar Market revenue (US$ Million) By Application, (US$ Million) 2021-2034
5.11.3. Middle East & Africa Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021-2034
5.11.4. Middle East & Africa Adalimumab Biosimilar Market revenue (US$ Million) by country, 2021-2034
Chapter 6. Competitive Landscape
6.1. Major Mergers and Acquisitions/Strategic Alliances
6.2. Company Profiles
6.2.1. Alvotech
6.2.2. Amgen Inc.
6.2.3. Biocon
6.2.4. Biosimilar Collaborations Ireland Limited
6.2.5. Boeheringer Ingelheim
6.2.6. Celltrion, Inc.
6.2.7. Coherus Biosciences
6.2.8. Cordavis Ltd.
6.2.9. Fresenius Kabi
6.2.10. Glenmark Pharmaceuticals
6.2.11. Hetero
6.2.12. Innovent Biologics
6.2.13. Kyowa Hakko Kirin (Fujifilm Kyowa Kirin Biologics)
6.2.14. Mylan
6.2.15. Mylan Pharmaceuticals Inc.
6.2.16. Organon & Co.
6.2.17. Organon/Samsung Bioepis
6.2.18. Pfizer
6.2.19. Samsung Bioepis
6.2.20. Sandoz
6.2.21. Stada Arzneimittel AG
6.2.22. Synermore
6.2.23. Teva
6.2.24. Torrent Pharmaceuticals
6.2.25. Zydus Cadila
6.2.26. Other prominent players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們